AAX Biotech is headed to BIO-Europe.

🚀 Next conference stop: BIO-Europe in Cologne Nov 8-11th! Our BD Manager Claudia Kielkopf will be attending and is looking to connect with partners and collaborators for our two proprietary technologies:
 
🧪 Opti-mAb®: A generally applicable linker technology that stabilizes scFvs and scFv-based multispecifics and CAR-T. Opti-mAb® significantly improves yield, stability and aggregation in these advanced therapeutics. The result? More reliable performance and the opportunity to push scFv-based therapeutics further.
 
🧬Seqitope®: Our high-throughput, high resolution epitope mapping technology that allows amino acid-resolution epitope mapping early in the discovery workflow.
 
👉 Do you work with scFvs and antibody development? Let’s meet and discuss! Book a meeting with Claudia here.